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It has been reported that chronic graft-versus-host disease (cGVHD) is associated with signiﬁcant morbidity
and mortality after allogeneic stem cell transplantation (allo-SCT). The risk of relapse is generally reduced
when cGVHD is present, but prognosis may be affected by increased toxicity and/or risk of infection associated
with immunosuppressive treatment (IST). We performed a longitudinal data analysis of cGVHD, including the
evolution of cGVHD itself over time in response to IST, in a single-center cohort of 313 consecutive patients
undergoing allo-SCT. We found that lack of sustained response without withdrawal of IST within 6 months of
cGVHD development was associated with higher transplantation-related mortality (hazard ratio, 2.32; 95%
conﬁdence interval, 1.24-4.33) compared with cGVHD-free patients. Conversely, response conferred better
overall survival (hazard ratio, 0.42; 95% conﬁdence interval, 0.18-0.95). Our analytical approach allowed us to
integrate the evolution of cGVHD in a predictive model of transplantation outcome; notably, remission
associated with permanent discontinuation of IST within the ﬁrst 6 months from the occurrence of cGVHD
seemed to correlate most closely with ﬁnal outcome. Further conﬁrmation from larger studies is needed.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION months or even years after allo-SCT, whereas extensive forms
Allogeneic hematopoietic stem cell transplantation
(allo-SCT) is an effective treatment for many hematologic
malignancies [1]. Allogeneic lymphocytes can produce
a graft-versus-malignancy (GVM) effect; thus cure after allo-
SCT may be stem from the elimination of malignant stem
cells or the establishment of a durable immune control on
their progeny [2]. Unfortunately, this beneﬁcial effect is
limited by graft-versus-host disease (GVHD), which is
responsible for most of the early and delayed mortality
occurring after allo-SCT.
Chronic GVHD (cGVHD) affects 30% to 70% of all allo-SCT
recipients who survive for 100 days, with a median onset of 4
to 6 months after transplantation [3]. cGVHD is associated
with very high morbidity and mortality and thus carries
a signiﬁcant medical burden in both affected patients and
society as a whole. As an example, the median time of
initiation of immunosuppressive treatment (IST) is 2 to 3
years after diagnosis of cGVHD, with 15% of patients
requiring IST even 7 years after diagnosis [4].
Patient outcomes related to the development of cGVHD
depend on disease severity and presentation. Limited forms
of cGVHD have been associated with prolonged survival
owing to the GVM effect, even if GVHD persists for severaledgments on page 582.
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12.12.016are associated mainly with increased transplantation-related
mortality (TRM) from infectious complications occurring
after IST [5,6]. In general, patients who develop GVHD are at
less risk for relapse, but this does not translate into better
survival in patients with acute GVHD (aGVHD) or severe
cGVHD, in whom the lower relapse risk is overcome by the
higher TRM due to GVHD itself [5,7].
As a late event, from a statistical standpoint, cGVHD is
usually analyzed as a time-dependent covariate to take into
account the temporal pattern of this late event and the
dynamic patient population at risk [8]; however, even in the
context of a time-dependent analysis of cGVHD, some limi-
tations exist. In fact, the event “chronic GVHD” is usually
considered single and invariable, occurring at a landmark
day from allo-SCT (ie, 6 months post transplantation) and
with a certain degree of severity (limited or extensive form,
according to the Seattle classiﬁcation scheme [9]). Actually,
cGVHD is a dynamic event that may persist for several
months or even years after allo-SCT and changes its features
along the time in terms of organ involved, speciﬁc treat-
ments, and global severity. Unfortunately, all of these
changes and the dynamic nature of cGVHD are not taken into
account by the current analytical methods, which still do not
make complete use of data.
The aim of the present analysis was to overcome current
analytical limitations by using longitudinal data in the
analysis of cGVHD to better predict transplantation
outcomes by capturing information on the evolution of
cGVHD over time. Internal preliminary analyses have sug-
gested that the initial presentation and severity of cGVHD, asTransplantation.
Figure 1. Multistep process after allo-SCT. AlloSCT indicates allogeneic stem
cell transplantation; TRM, transplant-related mortality.
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nosis, are predictive of ﬁnal outcome [10]. Here, we trans-
lated these elements into an analytical method capable of
capturing the event “sustained response to IST” in the
post-transplantation setting. Figure 1 shows the multistep
processes occurring during the post-transplantation period.
PATIENTS AND METHODS
Study Population
The study population comprised adult patients undergoing allo-SCT for
a hematologic malignancy after conditioning with a ﬂudarabine-busulfan-
antithymocyte globulin regimen as reported elsewhere [11,12] between
May 1999 and June 2010 at Institut Paoli-Calmettes (Marseille, France).
Indications for such a conditioning regimen in younger patients relied on
previous autologous SCT and/or presence of comorbidities precluding
administration of amyeloablative regimen owing to expected high regimen-
related toxicity. Cyclosporine alone, or in combination with mycophenolate
mofetil in cases with a mismatched unrelated donor, was administered as
GVHD prophylaxis, without methotrexate in accordance with local protocol
[11,12]. cGVHDwas classiﬁed retrospectively according to National Institutes
of Health (NIH) criteria as mild, moderate, or severe [13]. The duration of IST
was determined, and any changes in cGVHD severity over time were docu-
mented at 6-month intervals for up to 36 months, then annually thereafter.
Clinical and biological information allowed to calculate the organ-speciﬁc
and the global score at each timepoint. Information on cGVHD presentation
was collected: progressive, quiescent or de novo, aswell as classic, overlap, or
late-onset acute manifestations. An example of longitudinal data collection
and NIH-deﬁned classiﬁcation is provided in Appendix 1.
First-line systemic treatment of cGVHD was methylprednisolone 1 mg/
kg/day with or without cyclosporine. IST was initiated in the presence of an
extensive cGVHD according to the Seattle criteria [9]. Local steroids and/orFigure 2. Algorithm applied on IST lines. IST indicates immunosuppressive treatme
extracorporeal photoapheresis; RTX, rituximab; TLI, total lymphoid irradiation; GI, gaother treatments have been used for limited forms (eg, isolated oral, ocular,
or mild skin involvement). Various agents were used beyond the ﬁrst-line
treatment, according to clinical or biological manifestations, including
mycophenolate mofetil, methotrexate, extracorporeal photopheresis, rit-
uximab, total lymphoid irradiation, and imatinib [14-21]. Patients were
evaluated at the transplantation center at least every 3 to 6 months;
a further IST line was administered if no improvement of cGVHD occurred
within 6 months or progression was observed within 3 months from the
start of the previous IST line. An algorithm for choosing the proper drug
therapy is shown in Figure 2. The number of IST lines administered to each
patient was recorded as well.
Sustained response to IST was deﬁned as the complete disappearance of
all reversible clinical and/or biological manifestations of cGVHD together
with full and permanent IST withdrawal (ie, from severe form, coded as 3, to
resolution of cGVHD, coded as 0; see Appendix 1). If improvement or even
resolutionwas observed but the patient was still under IST, then cGVHDwas
coded as the previous time point, until deﬁnitive ISTwithdrawal occurred; in
that case, the patient was considered a complete responder and coded as 0.
Data on other important patient and transplantation characteristics
were collected, including patient age, diagnosis, disease risk at the time of
allo-SCT, donor type, stem cell source, comorbidity index [22], GVHD
prophylaxis, and platelet count at development of cGVHD. Data were
collected retrospectively from electronic clinical records. Data collection
started at the time of allo-SCT and continued until the last observation,
death from any cause, or relapse/progression of the original disease. The
study design was approved by the local Institutional Review Board.Statistical Analysis
Values are expressed as median (range) or number (percentage) as
applicable. Overall survival (OS) was estimated using the Kaplan-Meier
method [23]; cumulative incidence in the presence of competing risks
was calculated for TRM and relapse or progression [24]. cGVHD was
considered a time-dependent variable, and subsequent classiﬁcation was
assigned according to the response to ISTat 6,12,18, and 24months after the
occurrence of cGVHD.
Differences in OS and cause-speciﬁc risk for TRM and relapse/progres-
sion between responders and nonresponders after cGVHD were assessed
using Cox regression with time-dependent covariates [25]. Patients were
considered “without cGVHD” until cGVHD occurred, at which point they
were switched to the classiﬁcation “cGVHD with nonresponse to IST.”
Patients who responded to IST were switched to “cGVHD with response to
IST” at the time point of interest (6, 12, 18, or 24months after the occurrence
of cGVHD).
The combined role of form and presentation of cGVHD at baseline and
response status was assessed, and interaction was created and evaluated by
means of the likelihood ratio test, comparing models without interaction
and with interaction. Patients not evaluable for cGVHD owing to censoring
or occurrence before day þ100 post-HSCT were not considered in the
analysis for comparison of subsequent response to IST in patients with and
without cGVHD.
The impact of responders and nonresponders on cumulative incidence
of TRM or relapse/progression was estimated using two different landmarknt; MTX, methorexate; CsA, cyclosporine; MMF, mycophenolate mofetil; ECP,
stroinestinal.
Table 1
Patient and Transplantation Characteristics
Characteristic Value
Patients, n (%) 313 (100)
Age, years, median (range) 52 (18-70)
Diagnosis, n (%)
Acute leukemia 121 (39)
Myelodysplastic syndrome 22 (7)
Chronic myelogenous leukemia 16 (5)
Non-Hodgkin lymphoma 69 (22)
Hodgkin lymphoma 10 (3)
Multiple myeloma 48 (15)
Other 27 (9)
Comorbidity score, median (range) 2 (0-8)
Antithymocyte globulin total dose, n (%)
2.5 mg/kg 140 (45)
5 mg/kg 163 (52)
>5 mg/kg 10 (3)
Donor, n (%)
HLA-identical sibling 237 (76)
Unrelated donor 76 (24)
Stem cell source, n (%)
Bone marrow 18 (6)
Peripheral blood stem cells 295 (94)
GVHD prophylaxis, n (%)
Cyclosporine alone 270 (86)
Cyclosporine þ mycophenolate mofetil 43 (14)
IST lines, n, median (range) 1 (0-6)
Duration of IST, months, median (range) 21 (3-105)
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rately ﬁxed to detect patients with cGVHD. Then, second landmark points,
ﬁxed at 365 and 450 days post-SCT, respectively, were ﬁxed to allow
assessment of response/nonresponse within 6 months of cGVHD onset.
These landmark points were chosen to capture a sufﬁcient number of
patients without losing an excessive number of events, potentially leading to
loss of statistical power. TRM and relapsewere considered competing events
with one another, and a Fine and Gray competing-risks regression model
was used [26]. Hazard ratio (HR) for the Cox model and subhazard ratio
(SHR) for the FG model with respective 95% conﬁdence intervals (CI) were
provided for responders and nonresponders, with patients without cGVHD
serving as the reference group.
Adjustment forpatient age (continuousvariable),HLAmatchingbetween
patient and donor (HLA-identical vs HLA-mismatched), stem cell source
(bonemarrowvs peripheral blood stemcells), disease risk at time of allo-SCT,
and comorbidity index [22] (above vs below the median) was performed by
stepwise selection of variables with a P value < .15 on univariate analysis.
Disease risk at allo-SCT was considered standard for patients with acute
leukemia in ﬁrst complete remission and chronic myelogenous leukemia in
chronic phase, and high for all other patients.
To the illustrate the probability of OS and TRM or relapse/progression
according to response status after cGVHD, the multistate approach [27-29]
was used to obtain nonparametric transition probabilities among different
intermediate states (eg, cGVHD, response to IST) and ﬁnal states (eg, OS,
TRM/relapse).
The probability of singular ﬁnal events was calculated using the Aalen-
Johansen estimator for transition probabilities [30]. For nonresponders,
probability was calculated based on the status of “cGVHD without
response,” whereas for responders, probability was calculated as the like-
lihood of transition from the state of responder within 6 months of cGVHD
onset to the state of the ﬁnal event of interest.
Statistical analyses were performed using Stata version 11.0 (StataCorp,
College Station, TX) and R version 2.12.3 (mstate package; R Institute for
Statistical Computing, Vienna, Austria). A P value of .05 was considered
statistically signiﬁcant.
RESULTS
Patient and Transplantation Outcomes
A total of 313 patients meeting our inclusion criteria
underwent allo-SCTat our institution betweenMay 1999 and
June 2010. One-hundred twenty-nine of these patients
developed cGVHD,128 of whomwere evaluable for complete
data; 184 patients did not develop cGVHD. Median patient
age at allo-SCT was 52 years (range, 18-70 years). Patient and
transplantation characteristics are summarized in Table 1.
Median follow-up after allo-SCT was 30 months (range,
7-120 months). Data on comorbidity score were available for
271 patients (86%); median score was 2 (range, 0-8).
OS was 59% (95% CI, 53%-65%) at 3 years. Cumulative
incidences of TRM and relapse/progression at 3 years were
21% (95% CI, 17%-27%) and 22% (95% CI, 17%-27%), respec-
tively. A total of 159 patients (51%) developed aGVHD
(cumulative incidence, 50% [95% CI, 44%-55%]; median onset,
38 days post-SCT [range, 8-99 days]).
cGVHD
Among the 128 evaluable patients with cGVHD, 76
patients had previous aGVHD; 41 of these 76 patients pre-
sented with progressive cGVHD. Progressive cGVHD indi-
cated the onset of cGVHD without resolution of previous
existing aGVHD. Seventy-two patients developed aGVHD but
not cGVHD, 10 patients developed aGVHD and died before
day þ100 post-SCT, and 2 patients were censored before
day þ100. A total of 124 deaths were registered; 50 of these
patients had developed cGVHD before dying. Before
dayþ100, 19 patients died, and 6 were censored. The median
interval from allo-SCT to onset of cGVHD was 132 days
(range, 80-599 days); cumulative incidence was 45% (95% CI,
39%-51%).
According to the Seattle classiﬁcation scheme [9], 26
patients had limited cGVHD, and 102 patients had extensivecGVHD. Among the 26 patients with limited cGVHD, 16
patients had a moderate form, and 10 patients had a severe
form, according to NIH deﬁnitions [13]. The 102 patients with
extensive cGVHD included 14 with a mild form, 40 with
a moderate form, and 48 with a severe form. The 14 patients
with NIH-deﬁned mild cGVHD who were originally coded as
Seattle-deﬁned extensive vGVHD were reclassiﬁed as
previous aGVHD favorably evolving into progressive, late
acute, or overlap mild cGVHD after revision of patient
records. At presentation, features of cGVHD were “classic” in
75 patients and “overlap” in 10 patients. Forty-three patients
had late-onset aGVHD. Organs affected, as well as respective
scores at the onset of cGVHD, are detailed in Figure 3A. Skin,
liver, and mouth were most involved, whereas other organs,
such as lungs and articulations, were rarely involved at onset
(Figure 3A).The median number of administered IST lines
was 1 (range, 0-6), and themedian duration of IST among the
living patients was 21 months (range, 3-105 months).
Involved organs accounted for distinct patterns of NIH-
deﬁned severity scores at 6, 12, 18, and 24 months after
onset of cGVHD. Skin, mucosa, liver, and gastrointestinal
tract involvement declined over time, whereas eye and lung
involvement appeared to increase, especially between 6 and
12 months (Figure 3B).
Impact of cGVHD on Transplantation Outcomes
OS
The patients with cGVHD were divided into 2 groups
according to whether remission with permanent discontinu-
ation of IST was obtained (responders; n ¼ 60) or not (nonre-
sponders; n ¼ 68). Of note, 12 of the 68 nonresponders died
before 6 months after the onset of cGVHD, 11 due to cGVHD
itself and 1 due to relapse of underlying disease, despite severe
cGVHD. These 11 patients were considered nonresponders.
Among the 60 responders, 41 patients responded within 6
monthsof cGVHDonset, 8 respondedwithin12months, and11
responded beyond 18 months. The response rate within 6
months was slightly higher in patients with classic cGVHD
Figure 3. (A) Global and organ-speciﬁc scores at onset of cGVHD. (B) Organ-speciﬁc NIH-deﬁned severity at diagnosis of cGVHD and up to 24 months thereafter.
R. Crocchiolo et al. / Biol Blood Marrow Transplant 19 (2013) 576e583 579features (35%, vs 30% in patients with overlap cGVHD and 28%
in those with late-onset aGVHD), although the difference was
not statistically signiﬁcant (P ¼ .68).In the OS model for cGVHD, the unadjusted HR was 0.79
(95% CI, 0.52-1.19) for patients with cGVHD compared with
those without cGVHD (P ¼ .25). Only age and aGVHD were
Figure 4. (A) Predicted probability of death according to response at 6 months
after onset of cGVHD. (B) Predicted probabilities of TRM and relapse/
progression according to response at any time or at 6 months. Probabilities
were evaluated from the day of response to IST (for responders) or from the
day of development of cGVHD (for nonresponders).
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adjustment for these 2 variables. Unexpectedly, disease risk
did not affect OS in our series, possibly related to the rela-
tively high 3-year OS in our high-risk patients (58% [95% CI,
50%-65%] versus 60% [95% CI, 49%-70%] in standard-risk
patients; P ¼ .79). We found no signiﬁcant correlation
between comorbidity index score [22] and OS; however, it
must be noted that the score was calculated prospectively for
only the 122 patients (39%) who underwent allo-SCT in our
center since 2008.
When analyzing platelet count at the onset of cGVHD, we
found that a count <100  109/L was associated with higher
mortality risk (HR, 2.25; 95%CI,1.01-5.01;P¼ .05). Lowplatelet
countwas associatedwithmore aggressive features of cGVHD;
in fact, 65% of cGVHD events in patients presenting with
aplatelet count<100109/Lwereprogressive, comparedwith
only22%ofevents inpatientswithaplatelet count>100109/
L (P < .0001). Similarly, we found that NIH-deﬁned severity at
cGVHD onset was predictive of OS; mortality rate was 23% in
patients with a mild form, 30% in those with a moderate form,
and 59% in those with a severe form (P ¼ .002). Progressive-
onset cGVHD was associated with a 46% mortality rate,
compared with 35% of quiescent and de novo presentations,
a non statistically signiﬁcant difference (P ¼ .28).
In the model for response/nonresponse considering only
the patients who developed cGVHD, unadjusted HR was 0.46
(95% CI, 0.20-1.06) for responders at 6 months, 0.81 (95% CI,
0.19-3.55) for responders at 12 months, and 0.75 (95% CI,
0.17-3.30) for responders at 18 months or later compared
with the reference group of patients with cGVHD but with no
response over time. Globally, response status was not
signiﬁcantly associated with OS (P ¼ .28); only when
considering response at 6 months did we observe a trend
toward better OS among responders (P ¼ .09). In addition,
responders did better at 6 months than patients without
cGVHD (HR, 0.42; 95% CI, 0.18-0.95). Similar results were
obtained on multivariate analysis. The probability of death
according to response at 6 months is shown in Figure 4A.
Including the interaction term between form or presen-
tation and response status into the model for OS did not
signiﬁcantly change our results (P¼ .24, likelihood ratio test).
Of note, the beneﬁcial effect of response at 6 months was
comparable among the distinct types of cGVHD presentation
(P ¼ .83). Adjusted HRs are presented in Table 2.
A subanalysis looking at organ-speciﬁc response at 6
months detected a 26% organ-speciﬁc response rate, that is,
59 organs out of 225 affected at onset of cGVHD (Figure 3A).
In no speciﬁc organ was response signiﬁcantly associated
with overall response within 6 months (P > .05 for each
organ compared with average response of all organs), but
organ-speciﬁc responses were proportional to the absolute
number of organs involved at the onset of cGVHD (skin: 25 of
88; mouth: 9 of 40; eyes: 6 of 12; GI: 8 of 25; liver: 11 of 51;
lungs: 0 of 2; joints: 0 of 2; genitalia: 0 of 4; other: 0 of 1).
Consequently, no signiﬁcant association was found between
organ-speciﬁc response and OS.
TRM
Globally, the impact of response status was statistically
signiﬁcant (P ¼ .006). A higher risk for nonresponders (HR,
2.32; 95% CI, 1.24-4.33) compared with cGVHD-free patients
was observed, along with a trend toward decreased risk in
responders within 6 months (HR, 0.30; 95% CI, 0.04-2.36);
the difference between responders at 6 months and nonre-
sponders was signiﬁcant (P ¼ .047).After adjustment for age and aGVHD, the P value was
.06 for the difference between nonresponders versus
cGVHD-free patients and .04 for the difference between
nonresponders and responders at 6 months. The risk for TRM
was greater in nonresponders with moderate/severe cGVHD
compared with cGVHD-free patients (HR, 2.17; 95% CI, 1.12-
4.19; P ¼ .02). In contrast, the lack of sustained response to
IST at 6 months in patients with mild cGVHD did not result in
worse TRM in these patients compared with responders
(P ¼ .51). A platelet count <100  109/L was associated with
higher TRM (HR, 3.29; 95% CI, 1.41-7.70; P ¼ .006). Regarding
cGVHD presentation, progressive-onset cGVHD was associ-
ated with a 35% TRM compared with 21% for quiescent and
de novo forms (P ¼ .13).
Results of our landmark analysis are consistent with the
foregoing ﬁndings, as detailed in Appendix 2. Similar to OS,
we found no signiﬁcant association between organ-speciﬁc
response within 6 months post-SCT and TRM.
Table 2
Adjusted Hazard Ratios of OS, TRM and Relapse/Progression According to Response to IST and form of cGVHD
OS TRM Relapse/Progression
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Response to IST .17 .061 .18
No cGVHD 1.00 1.00 1.00
cGVHD, nonresponse 0.77 (0.50-1.20) 1.92 (1.01-3.66) 0.52 (0.25-1.09)
cGVHD, response at 6 months 0.42 (0.18-0.95) 0.24 (0.03-1.91) 0.82 (0.29-2.35)
cGVHD, response after 6 months 0.57 (0.19-1.73) 1.33 (0.26-6.95) 1.01 (0.20-5.08)
Response to IST and form of cGvHD .24 .04 .32
No cGVHD 1.00 1.00 1.00
Mild cGVHD, nonresponse 0.45 (0.18-1.14) 1.12 (0.36-3.41) 0.45 (0.11-1.94)
Moderate/severe cGVHD, nonresponse 0.86 (0.55-1.36) 2.17 (1.12-4.19) 0.53 (0.24-1.18)
Mild cGVHD, response at 6 months 0.38 (0.12-1.27) 0.53 (0.07-4.20) 0.41 (0.05-3.23)
Moderate/severe cGVHD, response at 6 months 0.45 (0.16-1.28) NE 1.09 (0.35-3.36)
Mild cGVHD, response after 6 months NE NE NE
Moderate/severe cGVHD, response after 6 months 0.74 (0.24-2.23) 1.71 (0.33-8.96) 1.38 (0.28-6.91)
NE indicates not evaluable owing to a lack of events in this category.
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Response to IST at any time had no signiﬁcant impact on
relapse or progression in both univariate and multivariate
analyses; the unadjusted HR was 0.49 (95% CI, 0.23-1.02) for
nonresponders versus cGVHD-free patients. No differences
were observed according to the form or presentation of
cGVHD. Results of relapse/progression by landmark analysis
were consistent, as detailed in Appendix 2. No associations
were identiﬁed between disease, disease stage, donor type,
or comorbidity score and relapse/progression. Probabilities
of TRM and relapse/progression according to response to IST
at 6 months post-SCT are shown in Figure 4B.
DISCUSSION
In this study, we speciﬁcally examined the impact of
response to immunosuppressive therapy for cGVHD on
transplantation outcomes. We found signiﬁcantly higher
TRM in patients who could not withdraw from IST within 6
months of onset of cGVHD comparedwith responders, which
translated into worse survival (Figure 4A). In addition,
nonresponders had signiﬁcantly higher TRM compared with
cGVHD-free patients (Table 2). No signiﬁcant impact on
relapse risk was seen in any group.
GVHD is associated with higher TRM and inferior survival,
as well as reduced risk of relapse owing to a GVM effect
[5,6,31-34]. In this study, we tried to overcome some
previous analytical limitations related to lack of data on
the evolution of cGVHD, as it appears in studies in which
information about cGVHD is not captured as a longitudinal
event and only data on occurrence, severity, and post
transplantation day are reported. We integrated the transi-
tion state “response to IST” at distinct time points from the
occurrence of cGVHD and found that remission associated
with sustainedwithdrawal (or not) at 6months fromonset of
cGVHD allowed us to create a predictive model capable of
predicting prognosis for cGVHD according to response to IST.
We found a higher TRM at 6-months post-SCT in nonre-
sponders compared with both responders and cGVHD-free
patients, independent of the initial presentation of cGVHD.
Importantly, the response to IST affected the prognosis
dictated by the initial form or presentation of cGVHD,
allowing us to improve and reﬁne our model. Interestingly,
lack of response to IST at 6 months in patients with mild
cGVHD did not result in higher TRM compared with
responders; most of these patients received topical rather
than systemic IST, which might explain the comparable
outcomes in the 2 groups. Moreover, the GVM effect waslikely preserved as long as only topical IST was administered.
In the transplantation setting, TRM is related to GVHD or
infection; here, TRM in nonresponders was due to cGVHD
itself, either directly or indirectly, given that the lack of
response required a more prolonged duration of IST and/or
the administration of further IST lines, thereby exposing
patients to life-threatening infections even if a response to
cGVHDwas ﬁnally obtained. Here, the shorter duration of IST
exposure among responders has proven beneﬁcial in this
sense and explains the lower TRM risk in this subset.
Although not the objective of the present study, our
results conﬁrm previous published ﬁndings on cGVHD and
transplantation outcomes [5,6,31-34]; however, we found no
statistically signiﬁcant correlation between cGVHD and
relapse or progression. This ﬁnding may be explained by our
small study sample and the fact that patients who became
responders disappeared from the cohort of nonresponders,
thus contributing to the progressive loss of power of our
comparisons. Another possible explanation is that diseases
known to be highly sensitive to the GVM effect, such as
chronic myelogenous leukemia or multiple myeloma, are
represented by few patients in this series (eg, 16 [5%] for the
former and 48 [15%] for the latter).
Our results are in line with a recent study by the Seattle
group in which resolution of GVHD followed by withdrawal
of IST was not associated with a subsequent increase in the
risk of relapse compared with patients without GVHD (in
whom withdrawal of IST was associated with a reduced risk
of relapse during the ﬁrst 18 months), but nonetheless was
considerably higher than that in patients with GVHD [35].
Our relatively limited study sample does not allow us to draw
deﬁnite conclusions about relapse/progression; however, we
found no increase in relapse in patients with cGVHD and
those who could withdraw from IST compared with patients
without cGVHD or nonresponders with cGVHD (Table 2).
Here, we propose a more comprehensive statistical
approach to the multifaceted and evolving behavior of
cGVHD, in an attempt to use the available data more
completely. Most published works have used the Kaplan-
Meier method [31], Cox regression with time-dependent
covariates [6,32,33], or competing-risk analysis without
time-dependent covariates [34]. We acknowledge that the
relatively small number of patients included in our analysis
represents a limitation, as does the study’s retrospective
nature, potentially leading to intrinsic bias in the grading of
cGVHD according to NIH criteria and/or in the evaluation of
response to IST.We cannot exclude the possibility of a relative
R. Crocchiolo et al. / Biol Blood Marrow Transplant 19 (2013) 576e582582underestimation of the involvement of some organs, such as
lungs andgenitalia (Figure3B), given thatpulmonary function
testing and physical examination of the genitalia were not
performed unless guided to do so by clinical complaints. On
the otherhand, our cohort appeared tobequitehomogeneous
in terms of cGVHD treatments and response assessments,
owing mainly to the study’s single-center design. Moreover,
the methodological approach was rather conservative in its
deﬁnition of “response to IST” and calculation of the time-
dependent transitional probabilities, compensating for the
relative narrowness of the study cohort.
Finally, our data suggest that evaluation of response to IST
within the ﬁrst 6 months after onset of cGVHDmerits further
exploration in larger series. It canbe speculated thatobtaining
a response within this interval may be a target for future
clinical studies in the cGVHD setting, with the objective of IST
withdrawal (or at least a signiﬁcant improvement with IST
tapering) as soon as possible, 6 months at the latest. The
“paradigm” of a steroid-based ﬁrst-line treatment with or
without a calcineurin inhibitor could be challenged in favor of
amore effective treatment for patientswith high-risk cGVHD.
For this reason, the ability to identify features of cGVHD that
are predictive of response to IST is of great interest.
In conclusion, the present study is the ﬁrst work to
speciﬁcally address the interpretation of cGVHD as
a dynamic, multistate variable. Remission associated with
permanent withdrawal of IST within 6 months of onset of
GVHD predicted transplantation outcome in this homoge-
neous monocenter population of 313 patients. Present data
may challenge current practices in managing cGVHD, with
the aim of optimizing treatment and preventing the some-
times fatal complications that remain associated with this
post-transplantation disease.
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R. Crocchiolo et al. / Biol Blood Marrow Transplant 19 (2013) 576e583 583APPENDIX 1. EXAMPLE OF LONGITUDINAL DATA COLLECTION AND NIH-DEFINED CLASSIFICATIONAPPENDIX 2. LANDMARK ANALYSIS(A) Using a landmark point of day þ180 from trans-
plantation, 100 patients had at that time already
developed cGvHD; response status at a landmark
point of day þ365 was considered.
An increase of cumulative incidence of TRM for patients
who developed cGvHD within 180 days was observed
(SHRadjusted (95% CI) ¼ 1.99 (0.97-4.10); P ¼ .06); when
response status at subsequent 6 months was assessed,
probability of TRM increased among non responders
compared with patients free from cGvHD: SHRadjusted (95%
CI) ¼ 3.87 (1.18-12.70); P ¼ .02. On the other hand, a trend
toward less TRM was observed among responders compared
with cGvHD-free patients: SHRadjusted (95% CI) ¼ 0.53
(0.06-4.54); P ¼ .56. Importantly, an almost signiﬁcant
difference between responders and non responders was
observed (P ¼ .06).In the relapse/progression model, the presence of cGvHD
wasnot associatedwithsigniﬁcantmodiﬁcation in cumulative
incidence of relapse: SHRadjusted (95% CI) ¼ 0.82 (0.41-1.63);
P¼ .56. According to response to IST, no signiﬁcant differences
(P ¼ .63) were noticed between responders (SHR [95% CI] ¼
0.83 [0.22-3.19]) and non responders (SHR [95% CI] ¼ 1.16
[0.45-2.98]) when compared with cGvHD-free patients.
(B) Using a landmark point of day þ260 from trans-
plantation, 155 patients had at that time already
developed cGvHD; response status at a landmark
point of day þ450 was considered.
Results on both TRM and relapse/progression were
similar to (A) (data not shown); P value of the difference
between responders and non responders was 0.10 for the
TRM model and 0.50 for the relapse/progression model.
